Effects of Pranlukast, a Leukotriene Receptor Antagonist, on Airway Inflammation in Mild Asthmatics

To determine the anti-inflammatory actions of pranlukast, a cysteinyl leuklotriene receptor antagonist, we measured exhaled nitric oxide (NO) concentrations and eosinophil ratio in induced sputum of three groups of mild asthmatics (n = 30): treated with bronchodilators alone, with bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 μg/day), and bronchodilators and pranlukast (450 mg/day). Pranlukast (450 mg/day) reduced the eosinophil ratio in the induced sputum significantly (p < 0.01) without a major effect on the concentration of exhaled NO. Pranlukast also increased values of peak expiratory flow significantly (p < 0.05). Pranlukast may be useful for mild asthmatics, in part through its ability to suppress eosinophilic airway infiltration.

[1]  W. Busse,et al.  Airway remodeling and repair. , 1999, American journal of respiratory and critical care medicine.

[2]  S. Wenzel.  Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No. , 1998, American journal of respiratory and critical care medicine.

[3]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[4]  Teruo Sakamoto,et al.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma , 1998, Thorax.

[5]  T. Reiss,et al.  A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. , 1998, The Journal of allergy and clinical immunology.

[6]  H. Boushey,et al.  Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. , 1998, The European respiratory journal.

[7]  T. Reiss,et al.  Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. , 1998, The European respiratory journal.

[8]  K. Kubo,et al.  Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. , 1997, Chest.

[9]  Q. Hamid,et al.  Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. , 1997, Journal of immunology.

[10]  R. Martin,et al.  Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. , 1997, American journal of respiratory cell and molecular biology.

[11]  S. Kudoh,et al.  Increased levels of nitric oxide derivatives in induced sputum in patients with asthma. , 1997, The Journal of allergy and clinical immunology.

[12]  P. O'Byrne,et al.  Induced sputum to assess airway inflammation in asthma. , 1996, The European respiratory journal.

[13]  D. Underwood,et al.  Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. , 1996, American journal of respiratory and critical care medicine.

[14]  M. Jordana,et al.  Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. , 1996, American journal of respiratory cell and molecular biology.

[15]  M. Jordana,et al.  Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. , 1995, American journal of respiratory cell and molecular biology.

[16]  P. Howarth,et al.  Epithelially derived endothelin and nitric oxide in asthma. , 1995, International archives of allergy and immunology.

[17]  P. Barnes,et al.  Nitric oxide and asthmatic inflammation. , 1995, Immunology today.

[18]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[19]  P. J. Barnes,et al.  Increased nitric oxide in exhaled air of asthmatic patients , 1994, The Lancet.

[20]  O. Zetterström,et al.  Single-breath nitric oxide measurements in asthmatic patients and smokers , 1994, The Lancet.

[21]  P. Howarth,et al.  Induction of nitric oxide synthase in asthma , 1993, The Lancet.

[22]  E. Weitzberg,et al.  Increased amount of nitric oxide in exhaled air of asthmatics. , 1993, The European respiratory journal.

[23]  C. van Weel,et al.  Slowing the Deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids: A 4-Year Prospective Study , 1993, Annals of Internal Medicine.

[24]  P. Jeffery,et al.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. , 1992, The American review of respiratory disease.

[25]  J. Denburg,et al.  Use of induced sputum cell counts to investigate airway inflammation in asthma. , 1992, Thorax.

[26]  J. Denburg,et al.  Cellular characteristics of sputum from patients with asthma and chronic bronchitis. , 1989, Thorax.

[27]  A. Woolcock,et al.  Rate of decline of lung function in subjects with asthma. , 1987, European journal of respiratory diseases.

[28]  S. Durham,et al.  Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. , 1997, American journal of respiratory cell and molecular biology.

[29]  D. Yates,et al.  Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. , 1996, American journal of respiratory and critical care medicine.

[30]  P. Paré,et al.  The mechanics of airway narrowing in asthma. , 1989, The American review of respiratory disease.